TCF7L2 and type 2 diabetes mellitus: TCF7L2 revealed a statistically significant decrease by 63% in the T2DM group when compared to the healthy controls (median = 0.3692; p < 0.0001), and a statistically significant decrease by 18% when comparing Charcot patients with healthy controls (median = 0.8224; p = 0.0136) (see Fig. 5).